-
Budget Impact Analysis of Hyaluronic Acid Viscosupplementation for Knee Osteoarthritis in Colombia
Sep 9, 2025, 16:22 PM -
Burden Of Disease, Healthcare Resource Use and Costs of Respiratory Syncytial Virus Among Adults in Spain in 2021-2023 in the Hospital Setting: A Real-World Retrospective Observational Study of Four Hospitals
Sep 9, 2025, 16:22 PM -
Retrospective Analysis of Hungarian HTA Submissions Under the Former National Health Economics Guideline
Sep 9, 2025, 16:22 PM -
Diabetes Trends in France (2021-2023): A Descriptive Study Based on the THIN Database
Sep 9, 2025, 16:22 PM -
To What Endpoint? Exploring Clinical Outcome Assessments of Pain in Phase 2 and 3 Trials and Drug Labels in Women’s Health Conditions
Sep 9, 2025, 16:22 PM -
Health-Related Quality of Life Impacts of Living With Primary Lateral Sclerosis (PLS): The Development of a Conceptual Model
Sep 9, 2025, 16:22 PM -
Does Insurance Value in Metastatic Breast Cancer Vary by Age Testing for Variation in Willingness to Pay for Novel Treatments Among Women in the US?
Sep 9, 2025, 16:22 PM -
Lean Assessment Process Methodology for RMD-Health: Evaluating Clinical Need Usefulness Adoption Barriers and Early Economic Value of AI in NHS Rheumatology Referrals
Sep 9, 2025, 16:22 PM -
Evaluating the Cost-Effectiveness of High-Dose Influenza Vaccination for Adults Aged 60 Years and Older in Austria
Sep 9, 2025, 16:22 PM -
Accounting for the Additional Uncertainty Following Rank-Preserving Structural Failure Time Model (RPSFTM) Crossover Adjustment in Survival Analysis: A Sage Approach
Sep 9, 2025, 16:22 PM -
Inequality in Vaccine Uptake: Lessons Learned From Denmark Analyzing Real-World Data From National Registries
Sep 9, 2025, 16:22 PM -
Economic Burden of Gaucher Disease: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Using Expert Consensus to Expand Access in Rare Disease Populations: Generating Evidence for Patients With Permanently Ventilated Spinal Muscular Atrophy
Sep 9, 2025, 16:22 PM -
Is Protocolized Stopping Lifelong Therapy With Eculizumab With Disease Monitoring and Retreatment for Eligible Atypical Hemolytic Uremic Syndrome (aHUS) Patients Cost-Effective? An Economic Evaluation of the SETS aHUS Trial
Sep 9, 2025, 16:22 PM -
Examining The Relationship Between Diabetes Mellitus and Eating Disorders
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Ocrelizumab for Treating Relapsing Multiple Sclerosis in Austria
Sep 9, 2025, 16:22 PM -
Systematic Review of Decision-Analytic Models Estimating the Economic Impact of Prescription Opioid Use and Associated Adverse Events
Sep 9, 2025, 16:22 PM -
From the Outside Looking in: Patient Advocacy Groups' and Healthcare Providers' Perspectives on Patient Engagement Strategies in the Israeli Health Technology Assessment Process
Sep 9, 2025, 16:22 PM -
Cardiovascular Effects of Semaglutide in Patients With Obesity, With or Without Type 2 Diabetes (T2DM): An Umbrella Review
Sep 9, 2025, 16:22 PM -
The Economic Case for Gender Equity: How Closing the Women’s Health Gap Benefits Healthcare Systems and Economies
Sep 9, 2025, 16:22 PM
